David Eber serves as the Director of Statistical Programming at Gilead Sciences, bringing nearly two decades of extensive experience in SAS programming and statistical analysis to the forefront of clinical development. His expertise encompasses a wide range of SAS tools, including SAS/BASE, SAS/STAT, and SAS/MACROS,...
David Eber serves as the Director of Statistical Programming at Gilead Sciences, bringing nearly two decades of extensive experience in SAS programming and statistical analysis to the forefront of clinical development. His expertise encompasses a wide range of SAS tools, including SAS/BASE, SAS/STAT, and SAS/MACROS, which he adeptly utilizes across both Windows and Unix platforms. David's role is pivotal in facilitating seamless communication between Gilead and its vendors, ensuring that the statistical programming and biostatistics contracts are managed effectively.
In his current position, David is instrumental in overseeing vendor relationships, addressing any issues that arise, and establishing robust vendor oversight processes for multiple statistical programming functions. His leadership extends to guiding statistical programming teams, where he occasionally takes on the role of Statistical Programming Lead, driving key projects that contribute to Gilead’s mission in biotechnology and oncology.
David's significant contributions to the development and implementation of technological infrastructures, such as e-CTD, e-NDA, and e-BLA, highlight his commitment to advancing clinical trials and ensuring compliance with FDA regulations. His proficiency in data manipulation, statistical analysis, and report generation positions him as a vital asset in the pharmaceutical industry, where he leverages his skills in Microsoft Excel and GCP to enhance the efficiency and accuracy of clinical development processes. As Gilead continues to innovate in the realm of biotechnology, David Eber remains at the helm of statistical programming, driving impactful results that shape the future of healthcare.
